Navigation Links
Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention
Date:6/12/2008

or attract key employees whose knowledge is essential to the development of our products; that unforeseen scientific difficulties develop with our process; that our patents are not sufficient to protect essential aspects of our technology; that competitors may invent better technology; that our products may not work as well as hoped or worse, that our products may harm recipients; and that we may not be able to raise sufficient funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in our filings from time to time with the Securities and Exchange Commission (the "SEC"), which we strongly urge you to read and consider, including our Registration Statement on Form SB-2, as amended, that was declared effective on July 10, 2006; our annual report on Form 10-KSB filed with the SEC on November 14, 2007; and our Form 10-QSB filed with the SEC on April 15, 2008, all of which are available free of charge on the SEC's web site at http://www.sec.gov. Subsequent written and oral forward-looking statements attributable to us or to persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth in our reports filed with the SEC. We expressly disclaim any intent or obligation to update any forward-looking statements.

For more information, please contact:

The Ruth Group

Sara Ephraim (investors) Janine McCargo (media)

(646) 536-7002 (646) 536-7033

sephraim@theruthgroup.com jmcc
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Raptor Pharmaceuticals Acquires Orphan Clinical Program
2. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
3. Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... and SHENZHEN, China , July 31, ... the purchase of an Irys™System by ... BioNano,s platform to enable comprehensive exploration of human structural ... various organisms of interest, including those where no reference ... to develop new methods for multiplexing on the Irys ...
(Date:7/31/2014)... July 31, 2014 “Rapid technological ... across the U.S., increasing unemployment, depressing American consumer ... It is a Catch 22—we need automated manufacturing ... means fewer jobs,” says economist and corporate relocation ... Corporate Top 10 Pro-Business States for 2014, co-published ...
(Date:7/31/2014)... 2014 Sales Horizons, a leader in ... sales training course – Mastering the Complex Sale ... , Drawn from proven sales training programs used by ... Complex Sale online sales training course is available to ... face-to-face contact with customers, like technical support, engineers, clinical ...
(Date:7/30/2014)... 2014 A study presented at the ... efficacy of CSL Behring,s C1 Inhibitor (C1-INH) concentrate ... highly sensitized patients. C1-INH is a human protein ... The study shows that post-transplant treatment ... levels of complement components 3 and 4, suggesting ...
Breaking Biology Technology:BioNano Genomics Announces the Purchase of the Irys System by BGI 2BioNano Genomics Announces the Purchase of the Irys System by BGI 3BioNano Genomics Announces the Purchase of the Irys System by BGI 4ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 2ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 3ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 4Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 2Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 3Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3
... see it, soon you might not, researchers at the ... researchers have demonstrated an approximate cloaking effect created by ... brings scientists a step closer to a practical solution ... a theoretical exercise," said Harley Johnson, a Cannon Faculty ...
... paper titled “Avanta AC™ Advanced Ceramics Solutions ... This white paper outlines the challenges in ... scale, as well as the advantages of ... nanopowders are critical to a variety of ...
... Excellence in Emerging Category, LOS ANGELES, June ... that Dr. Donald Rice, Founder, President, & CEO,received ... 2008 Award in the,Emerging category in the Greater ... the award recognizes outstanding entrepreneurs who are building,and ...
Cached Biology Technology:Silicon photonic crystals key to optical cloaking, researchers say 2 SACHEM Launches New Products for High Purity Advanced Ceramic Powders : Avanta AC™ Advanced Ceramics Solutions Offer Unique Advantages over Inorganic Bases in the Manufacture of Advanced Ceramic Nanoparticles 2Agensys Founder, President, & CEO Dr. Donald Rice Named Ernst & Young Entrepreneur Of The Year(R) 2008 Award Winner for the Greater Los Angeles Area 2Agensys Founder, President, & CEO Dr. Donald Rice Named Ernst & Young Entrepreneur Of The Year(R) 2008 Award Winner for the Greater Los Angeles Area 3
(Date:7/31/2014)... the photovoltaic effect in 1839, humankind has sought to ... its own purposes. In a new research report published ... FASEB Journal , scientists may have uncovered a ... focusing on a naturally occurring combination of lipids that ... over time and across speciessuggests that this specific natural ...
(Date:7/31/2014)... New Orleans, LA Dr. Oren Tessler, Assistant Professor ... Orleans School of Medicine, is part of a team ... success rate using a method to screen and select ... than 90% of the patients who underwent this surgery ... and also got a bonus cosmetic eyelid surgery. The ...
(Date:7/31/2014)... Florida , July 31, 2014 ... develop unique and innovative smart technologies; companies turn towards ... EBAY ), Amazon.com Inc. (NASDAQ: ... Google Inc. (NASDAQ: GOOG ) and Microsoft ... authentication company focused on the growing m-commerce market, announces ...
Breaking Biology News(10 mins):Scientists shine bright new light on how living things capture energy from the sun 2Surgeons report significant migraine relief from cosmetic eyelid surgery technique 2Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 2Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 3Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 4Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 5Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 6
... has developed a calcium phosphate-based supplement that -- even ... thickness without the side effects of many current drug ... and Biomimetics and of Implant Dentistry, presented her research ... Research annual meeting on March 9, 2006. ...
... Medical Center shows that on a biochemical level, hormone-like ... the way in which certain hormones work in humans ... that afflict a third of the world's population. , ... genes involved in the development and reproduction of Caenorhabditis ...
... "pumps" associated with multi-drug resistance in bacteria may also ... a process known as quorum sensing, said researchers from ... online today in the Proceedings of the National Academy ... by these pumps may actually be similar in structure ...
Cached Biology News:New study reveals promising osteoporosis treatment 2Worm hormone discovery may aid fight against parasitic disease 2Worm hormone discovery may aid fight against parasitic disease 3Drug resistance may travel same path as quorum sensing 2
...
MOUSE ANTI PORCINE SLA 1:FITC Immunogen: Porcine peripheral blood mononuclear cells....
This antibody detects an ~92 kDa protein corresponding to the apparent molecular mass of the beta subunit of Hypoxia Inducible Factor-1 (HIF-1beta) on Western blots....
...
Biology Products: